Chemical Compound Review:
Tenormin 2-[4-[2-hydroxy-3-(propan-2...
Synonyms:
Atcardil, Atehexal, Atenolin, Atenomel, atenolol, ...
Black,
Elliott,
Grandits,
Grambsch,
Lucente,
White,
Neaton,
Grimm,
Hansson,
Lacourciere,
Muller,
Sleight,
Weber,
Williams,
Wittes,
Zanchetti,
Anders,
Silvestri,
Galetta,
Cerquetani,
Marazzi,
Patrizi,
Fini,
Rosano,
Lindholm,
Ibsen,
Dahlöf,
Devereux,
Beevers,
de Faire,
Fyhrquist,
Julius,
Kjeldsen,
Kristiansson,
Lederballe-Pedersen,
Nieminen,
Omvik,
Oparil,
Wedel,
Aurup,
Edelman,
Snapinn,
Hallberg,
Karlsson,
Kurland,
Lind,
Kahan,
Malmqvist,
Ohman,
Nyström,
Melhus,
Brown,
Palmer,
Castaigne,
de Leeuw,
Mancia,
Rosenthal,
Ruilope,
Kurland,
Melhus,
Karlsson,
Kahan,
Malmqvist,
Ohman,
Nyström,
Hägg,
Lind,
- The effects of antihypertensive therapy on left ventricular mass in elderly patients. Schulman, S.P., Weiss, J.L., Becker, L.C., Gottlieb, S.O., Woodruff, K.M., Weisfeldt, M.L., Gerstenblith, G. N. Engl. J. Med. (1990)
- Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. Mangano, D.T., Layug, E.L., Wallace, A., Tateo, I. N. Engl. J. Med. (1996)
- Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. Black, H.R., Elliott, W.J., Grandits, G., Grambsch, P., Lucente, T., White, W.B., Neaton, J.D., Grimm, R.H., Hansson, L., Lacourciere, Y., Muller, J., Sleight, P., Weber, M.A., Williams, G., Wittes, J., Zanchetti, A., Anders, R.J. JAMA (2003)
- Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Yusuf, S., Ramsdale, D., Peto, R., Furse, L., Bennett, D., Bray, C., Sleight, P. Lancet (1980)
- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lindholm, L.H., Ibsen, H., Dahlöf, B., Devereux, R.B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S.E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., Snapinn, S. Lancet (2002)
- Randomized clinical trial of atenolol in patients with alcohol withdrawal. Kraus, M.L., Gottlieb, L.D., Horwitz, R.I., Anscher, M. N. Engl. J. Med. (1985)
- Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Liebowitz, M.R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R. Arch. Gen. Psychiatry (1992)
- Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Rosenthal, N.E., Jacobsen, F.M., Sack, D.A., Arendt, J., James, S.P., Parry, B.L., Wehr, T.A. The American journal of psychiatry. (1988)
- Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Silvestri, A., Galetta, P., Cerquetani, E., Marazzi, G., Patrizi, R., Fini, M., Rosano, G.M. Eur. Heart J. (2003)
- Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists. Frishman, W.H. N. Engl. J. Med. (1982)
- Letter: Atenolol and renin release. Sassard, J., Pozet, N., Vincent, M., Zech, P.Y. N. Engl. J. Med. (1976)
- Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. Kjeldsen, S.E., Dahlöf, B., Devereux, R.B., Julius, S., Aurup, P., Edelman, J., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparil, S., Snapinn, S., Wedel, H. JAMA (2002)
- Metoprolol or atenolol for mild-to-moderate hypertension. Lyngstam, O., Rydén, L. Lancet (1979)
- Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Helgeland, A., Strømmen, R., Hagelund, C.H., Tretli, S. Lancet (1986)
- Reduction of stress/catecholamine-induced cardiac necrosis by beta 1-selective blockade. Cruickshank, J.M., Neil-Dwyer, G., Degaute, J.P., Hayes, Y., Kuurne, T., Kytta, J., Vincent, J.L., Carruthers, M.E., Patel, S. Lancet (1987)
- Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Oberman, A., Wassertheil-Smoller, S., Langford, H.G., Blaufox, M.D., Davis, B.R., Blaszkowski, T., Zimbaldi, N., Hawkins, C.M. Ann. Intern. Med. (1990)
- Effect of treatment of isolated systolic hypertension on left ventricular mass. Ofili, E.O., Cohen, J.D., St Vrain, J.A., Pearson, A., Martin, T.J., Uy, N.D., Castello, R., Labovitz, A.J. JAMA (1998)
- Atenolol: once-daily cardioselective beta blockade for angina pectoris. Jackson, G., Schwartz, J., Kates, R.E., Winchester, M., Harrison, D.C. Circulation (1980)
- Effect of atenolol on left ventricular function in hypertensive patients. Ibrahim, M.M., Madkour, M.A., Mossallam, R. Circulation (1980)
- Stereoselective release of (S)-atenolol from adrenergic nerve endings at exercise. Stoschitzky, K., Lindner, W., Klein, W. Lancet (1992)
- Endothelial modulation of beta-adrenergic dilation of large coronary arteries in conscious dogs. Ghaleh, B., Béa, M.L., Dubois-Randé, J.L., Giudicelli, J.F., Hittinger, L., Berdeaux, A. Circulation (1995)
- Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. Balijepalli, R.C., Foell, J.D., Hall, D.D., Hell, J.W., Kamp, T.J. Proc. Natl. Acad. Sci. U.S.A. (2006)
- Effects of selective and nonselective beta-adrenergic blockade on mechanisms of exercise conditioning. Wolfel, E.E., Hiatt, W.R., Brammell, H.L., Carry, M.R., Ringel, S.P., Travis, V., Horwitz, L.D. Circulation (1986)
- Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Bandyopadhyay, S., Klaunig, J.E., Somani, P. Hepatology (1990)
- Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Roberts, D.H., Tsao, Y., McLoughlin, G.A., Breckenridge, A. Lancet (1987)
- Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Telford, A.M., Wilson, C. Lancet (1981)
- Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Giugliano, D., Acampora, R., Marfella, R., De Rosa, N., Ziccardi, P., Ragone, R., De Angelis, L., D'Onofrio, F. Ann. Intern. Med. (1997)
- Beta 2-adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria. Rump, L.C., Schwertfeger, E., Schaible, U., Fraedrich, G., Schollmeyer, P. Circ. Res. (1994)
- Atenolol enhances nocturnal growth hormone (GH) release in GH-deficient children during long term GH-releasing hormone therapy. Martha, P.M., Blizzard, R.M., Thorner, M.O., Rogol, A.D. J. Clin. Endocrinol. Metab. (1990)
- Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Kurland, L., Melhus, H., Karlsson, J., Kahan, T., Malmqvist, K., Ohman, P., Nyström, F., Hägg, A., Lind, L. J. Hypertens. (2002)
- The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Hallberg, P., Karlsson, J., Kurland, L., Lind, L., Kahan, T., Malmqvist, K., Ohman, K.P., Nyström, F., Melhus, H. J. Hypertens. (2002)
- NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. E, L., M, M., M, C., T, M., T, T., H M, S. Int. J. Cancer (2006)
- Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Brown, M.J., Palmer, C.R., Castaigne, A., de Leeuw, P.W., Mancia, G., Rosenthal, T., Ruilope, L.M. Lancet (2000)